Clinical Trial Detail

NCT ID NCT04241185
Title Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

urinary bladder cancer

Therapies

Pembrolizumab

Cisplatin

Mitomycin C

Gemcitabine

Fluorouracil

Age Groups: adult senior

No variant requirements are available.